Transplantation of stem cells has shown promise for improving functional recovery for alzheimer’s disease. Mesenchyme stem cells could promote survival, increased the metabolic activity and help to rescue the alzheimers disease cell model in vitro. The coculture of human mesenchyme stem cells and BV-2, mouse microglia, increased neprilysine expression, the beta-amyloid-degrading enzyme, under the exposure beta-amyloid. The transplantations of human and mouse mesenchymal stem cells were shown to reduce beta-amyloid deposition, to improved memory and to alleviate the alzheimers disease pathology in alzheimers disease mouse models. Mouse neural stem cells were colonized around amyloid plaques and modified to express metalloproteinase 9 (MMP9), a secreted protease reported to degrade aggregated Ab peptides, whereas these neural stem cells didn’t migrate into other regions after transplantation in alzheimers disease mouse brain. Alzheimers disease stem cells also improved alzheimers disease pathology involving reduction of beta-amyloid deposition and memory improvement due to decreasing of proinflammatory factors. Human amniotic epithelial cells were observed their survivals and no any immune rejection for 8 weeks.